Related Experiment Video
Updated: Jun 15, 2026

Three-Dimensional Cell Culture Models to Investigate the Epithelial Barrier in Eosinophilic Esophagitis
Published on: May 10, 2024
Non-surgical interventions for eosinophilic esophagitis
Elizabeth J Elliott1, Diana Thomas, Jonathan E Markowitz
1a) Professor of Paediatrics and Child Health, Sydney Medical School, The University of Sydney; b) Director, Centre for Evidence Based Paediatric Gastroenterology and Nutrition (CEBPGAN), The Children's Hospital at Westmead, Locked Bag 4001, Westmead, NSW, Australia, 2145.
Limited trials show topical fluticasone may help vomiting in eosinophilic esophagitis (EE), but more research is needed. Current treatments for EE have variable effectiveness and potential harms.
Area of Science:
- Gastroenterology
- Immunology
- Clinical Trials
Background:
- Eosinophilic esophagitis (EE) presents with esophageal symptoms, elevated eosinophils, and lack of response to acid suppressants.
- The etiology of EE is unknown, with potential contributions from dietary, environmental, and immunological factors.
- Current treatments for EE, including steroids and immune modulators, lack a universal approach.
Purpose of the Study:
- To evaluate the benefits and harms of medical interventions for eosinophilic esophagitis (EE).
Main Methods:
- Searched multiple databases (Cochrane, MEDLINE, EMBASE) up to February 2009.
- Included randomized controlled trials (RCTs) comparing EE interventions with placebo or other treatments.
- Two independent reviewers screened abstracts and collected data.
Main Results:
- Topical fluticasone showed benefit in reducing vomiting but not dysphagia compared to placebo.
- Fluticasone and prednisone had similar symptom resolution, but prednisone had more adverse effects.
- Mepolizumab reduced esophageal eosinophil counts but not symptoms compared to placebo.
Conclusions:
- Limited RCT data restricts comprehensive comparison of EE treatment benefits and harms.
- Further RCTs are necessary to establish effective therapies for eosinophilic esophagitis.
More Related Videos
Related Concept Videos
Esophageal Strictures-II: Clinical Features and Management
Healthcare providers should gather a comprehensive medical history and conduct a physical examination for diagnosis. If esophageal stricture is...
Gastroesophageal Reflux Disease II: Clinical Features and Management
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Barrett Esophagus-II: Clinical Manifestations and Management
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure entails...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Esophageal Strictures-I: Introduction
Etiology
The primary cause of esophageal strictures is long-standing gastroesophageal reflux disease (GERD), accounting for about 70 to 80% of adult cases. Chronic acid reflux can lead to injury and scarring of the esophageal lining, culminating in...

